Toll-Like Receptors in Liver Disease

Advances in Clinical Chemistry

Volumn 59, Issue , 2013, Pages 155-201

  Petrasek, Jan ^a   Csak, Timea ^a   Szabo, Gyongyi ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870986481     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-405211-6.00006-1     Document Type: Chapter

References (302)

1. Minino A.M., Heron M.P., Murphy S.L., Kochanek K.D., Centers for Disease Control and Prevention National Center for Health Statistics National Vital Statistics System Deaths: final data for 2004. Natl. Vital Stat. Rep. 2007, 55:1-119.
2. Corrao G., Ferrari P., Zambon A., Torchio P., Arico S., Decarli A. Trends of liver cirrhosis mortality in Europe, 1970-1989: age-period-cohort analysis and changing alcohol consumption. Int. J. Epidemiol. 1997, 26:100-109.
3. Burroughs A., McNamara D. Liver disease in Europe. Aliment. Pharmacol. Ther. 2003, 18(Suppl. 3):54-59.
4. Kim W.R., Brown R.S., Terrault N.A., El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002, 36:227-242.
5. Li Z., Diehl A.M. Innate immunity in the liver. Curr. Opin. Gastroenterol. 2003, 19:565-571.
6. Petrasek J., Mandrekar P., Szabo G. Toll-like receptors in the pathogenesis of alcoholic liver disease. Gastroenterol. Res. Pract. 2010, 2010. 710381 (Epub 2010 Aug 17).
7. Szabo G., Mandrekar P. A recent perspective on alcohol, immunity, and host defense. Alcohol. Clin. Exp. Res. 2009, 33:220-232.
8. Machida K., Tsukamoto H., Mkrtchyan H., Duan L., Dynnyk A., Liu H.M., Asahina K., Govindarajan S., Ray R., Ou J.H., et al. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc. Natl. Acad. Sci. USA. 2009, 106:1548-1553.
9. Moritoki Y., Lian Z.X., Wulff H., Yang G.X., Chuang Y.H., Lan R.Y., Ueno Y., Ansari A.A., Coppel R.L., Mackay I.R., et al. AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology 2007, 45:314-322.
10. Karrar A., Broome U., Sodergren T., Jaksch M., Bergquist A., Bjornstedt M., Sumitran-Holgersson S. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology 2007, 132:1504-1514.
11. Imaeda A.B., Watanabe A., Sohail M.A., Mahmood S., Mohamadnejad M., Sutterwala F.S., Flavell R.A., Mehal W.Z. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J. Clin. Invest. 2009, 119:305-314.
12. Lang K.S., Recher M., Junt T., Navarini A.A., Harris N.L., Freigang S., Odermatt B., Conrad C., Ittner L.M., Bauer S., et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 2005, 11:138-145.
13. Seki E., De Minicis S., Osterreicher C.H., Kluwe J., Osawa Y., Brenner D.A., Schwabe R.F. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 2007, 13:1324-1332.
14. Tsuchihashi S., Zhai Y., Bo Q., Busuttil R.W., Kupiec-Weglinski J.W. Heme oxygenase-1 mediated cytoprotection against liver ischemia and reperfusion injury: inhibition of type-1 interferon signaling. Transplantation 2007, 83:1628-1634.
15. Ma L.L., Gao X., Liu L., Xiang Z., Blackwell T.S., Williams P., Chari R.S., Yin D.P. CpG oligodeoxynucleotide triggers the liver inflammatory reaction and abrogates spontaneous tolerance. Liver Transpl. 2009, 15:915-923.
16. Mencin A., Kluwe J., Schwabe R.F. Toll-like receptors as targets in chronic liver diseases. Gut 2009, 58:704-720.
17. Gao B., Jeong W.I., Tian Z. Liver: an organ with predominant innate immunity. Hepatology 2008, 47:729-736.
18. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
19. De Creus A., Abe M., Lau A.H., Hackstein H., Raimondi G., Thomson A.W. Low TLR4 expression by liver dendritic cells correlates with reduced capacity to activate allogeneic T cells in response to endotoxin. J. Immunol. 2005, 174:2037-2045.
20. Seki E., Brenner D.A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008, 48:322-335.
21. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2001, 2:675-680.
22. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
23. Raetz C.R., Reynolds C.M., Trent M.S., Bishop R.E. Lipid A modification systems in gram-negative bacteria. Annu. Rev. Biochem. 2007, 76:295-329.
24. Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J., Mathison J.C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249:1431-1433.
25. Shimazu R., Akashi S., Ogata H., Nagai Y., Fukudome K., Miyake K., Kimoto M. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 1999, 189:1777-1782.
26. Wright S.D., Tobias P.S., Ulevitch R.J., Ramos R.A. Lipopolysaccharide (LPS) binding protein opsonizes LPS-bearing particles for recognition by a novel receptor on macrophages. J. Exp. Med. 1989, 170:1231-1241.
27. Takeda K., Takeuchi O., Akira S. Recognition of lipopeptides by Toll-like receptors. J. Endotoxin Res. 2002, 8:459-463.
28. Uematsu S., Fujimoto K., Jang M.H., Yang B.G., Jung Y.J., Nishiyama M., Sato S., Tsujimura T., Yamamoto M., Yokota Y., et al. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat. Immunol. 2008, 9:769-776.
29. Kawai T., Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann. N. Y. Acad. Sci. 2008, 1143:1-20.
30. Kawai T., Akira S. Innate immune recognition of viral infection. Nat. Immunol. 2006, 7:131-137.
31. Kawai T., Akira S. TLR signaling. Semin. Immunol. 2007, 19:24-32.
32. Huck S., Deveaud E., Namane A., Zouali M. Abnormal DNA methylation and deoxycytosine-deoxyguanine content in nucleosomes from lymphocytes undergoing apoptosis. FASEB J. 1999, 13:1415-1422.
33. Akira S., Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004, 4:499-511.
34. Kagan J.C., Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 2006, 125:943-955.
35. Rowe D.C., McGettrick A.F., Latz E., Monks B.G., Gay N.J., Yamamoto M., Akira S., O'Neill L.A., Fitzgerald K.A., Golenbock D.T. The myristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction. Proc. Natl. Acad. Sci. USA. 2006, 103:6299-6304.
36. Ruiter D.J., van der Meulen J., Brouwer A., Hummel M.J., Mauw B.J., van der Ploeg J.C., Wisse E. Uptake by liver cells of endotoxin following its intravenous injection. Lab. Invest. 1981, 45:38-45.
37. Zarember K.A., Godowski P.J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 2002, 168:554-561.
38. Su G.L., Klein R.D., Aminlari A., Zhang H.Y., Steinstraesser L., Alarcon W.H., Remick D.G., Wang S.C. Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and toll-like receptor 4. Hepatology 2000, 31:932-936.
39. Van Bossuyt H., De Zanger R.B., Wisse E. Cellular and subcellular distribution of injected lipopolysaccharide in rat liver and its inactivation by bile salts. J. Hepatol. 1988, 7:325-337.
40. Fox E.S., Thomas P., Broitman S.A. Clearance of gut-derived endotoxins by the liver. Release and modification of 3H, 14C-lipopolysaccharide by isolated rat Kupffer cells. Gastroenterology 1989, 96:456-461.
41. Tanikawa K., Mimura Y., Sakisaka S., Noguchi K. Role of hepatocytes in the clearance of lipopolysaccharide and its clinical significance. Prog. Clin. Biol. Res. 1998, 397:191-198.
42. Seki E., Tsutsui H., Nakano H., Tsuji N., Hoshino K., Adachi O., Adachi K., Futatsugi S., Kuida K., Takeuchi O., et al. Lipopolysaccharide-induced IL-18 secretion from murine Kupffer cells independently of myeloid differentiation factor 88 that is critically involved in induction of production of IL-12 and IL-1beta. J. Immunol. 2001, 166:2651-2657.
43. Seki E., Tsutsui H., Tsuji N.M., Hayashi N., Adachi K., Nakano H., Futatsugi-Yumikura S., Takeuchi O., Hoshino K., Akira S., et al. Critical roles of myeloid differentiation factor 88-dependent proinflammatory cytokine release in early phase clearance of Listeria monocytogenes in mice. J. Immunol. 2002, 169:3863-3868.
44. Kopydlowski K.M., Salkowski C.A., Cody M.J., van Rooijen N., Major J., Hamilton T.A., Vogel S.N. Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J. Immunol. 1999, 163:1537-1544.
45. Schwabe R.F., Seki E., Brenner D.A. Toll-like receptor signaling in the liver. Gastroenterology 2006, 130:1886-1900.
46. Lichtman S.N., Wang J., Lemasters J.J. LPS receptor CD14 participates in release of TNF-alpha in RAW 264.7 and peritoneal cells but not in kupffer cells. Am. J. Physiol. 1998, 275:G39-G46.
47. Knolle P., Schlaak J., Uhrig A., Kempf P., Meyer zum Buschenfelde K.H., Gerken G. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J. Hepatol. 1995, 22:226-229.
48. Scott M.J., Billiar T.R. Beta2-integrin-induced p38 MAPK activation is a key mediator in the CD14/TLR4/MD2-dependent uptake of lipopolysaccharide by hepatocytes. J. Biol. Chem. 2008, 283:29433-29446.
49. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005, 115:209-218.
50. Brun P., Castagliuolo I., Pinzani M., Palu G., Martines D. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289:G571-G578.
51. Gabele E., Muhlbauer M., Dorn C., Weiss T.S., Froh M., Schnabl B., Wiest R., Scholmerich J., Obermeier F., Hellerbrand C. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem. Biophys. Res. Commun. 2008, 376:271-276.
52. Harada K., Ohira S., Isse K., Ozaki S., Zen Y., Sato Y., Nakanuma Y. Lipopolysaccharide activates nuclear factor-kappaB through toll-like receptors and related molecules in cultured biliary epithelial cells. Lab. Invest. 2003, 83:1657-1667.
53. Chen X.M., O'Hara S.P., Nelson J.B., Splinter P.L., Small A.J., Tietz P.S., Limper A.H., LaRusso N.F. Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation of NF-kappaB. J. Immunol. 2005, 175:7447-7456.
54. Uhrig A., Banafsche R., Kremer M., Hegenbarth S., Hamann A., Neurath M., Gerken G., Limmer A., Knolle P.A. Development and functional consequences of LPS tolerance in sinusoidal endothelial cells of the liver. J. Leukoc. Biol. 2005, 77:626-633.
55. Martin-Armas M., Simon-Santamaria J., Pettersen I., Moens U., Smedsrod B., Sveinbjornsson B. Toll-like receptor 9 (TLR9) is present in murine liver sinusoidal endothelial cells (LSECs) and mediates the effect of CpG-oligonucleotides. J. Hepatol. 2006, 44:939-946.
56. Wu J., Lu M., Meng Z., Trippler M., Broering R., Szczeponek A., Krux F., Dittmer U., Roggendorf M., Gerken G., et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007, 46:1769-1778.
57. Asselin-Paturel C., Brizard G., Pin J.J., Briere F., Trinchieri G. Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J. Immunol. 2003, 171:6466-6477.
58. Shu S.A., Lian Z.X., Chuang Y.H., Yang G.X., Moritoki Y., Comstock S.S., Zhong R.Q., Ansari A.A., Liu Y.J., Gershwin M.E. The role of CD11c(+) hepatic dendritic cells in the induction of innate immune responses. Clin. Exp. Immunol. 2007, 149:335-343.
59. Lau A.H., Szabo G., Thomson A.W. Antigen-presenting cells under the influence of alcohol. Trends Immunol. 2009, 30:13-22.
60. Mathison J.C., Ulevitch R.J. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J. Immunol. 1979, 123:2133-2143.
61. Uesugi T., Froh M., Arteel G.E., Bradford B.U., Thurman R.G. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 2001, 34:101-108.
62. Adachi Y., Bradford B.U., Gao W., Bojes H.K., Thurman R.G. Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology 1994, 20:453-460.
63. Koop D.R., Klopfenstein B., Iimuro Y., Thurman R.G. Gadolinium chloride blocks alcohol-dependent liver toxicity in rats treated chronically with intragastric alcohol despite the induction of CYP2E1. Mol. Pharmacol. 1997, 51:944-950.
64. Iimuro Y., Gallucci R.M., Luster M.I., Kono H., Thurman R.G. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997, 26:1530-1537.
65. Uesugi T., Froh M., Arteel G.E., Bradford B.U., Wheeler M.D., Gabele E., Isayama F., Thurman R.G. Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice. J. Immunol. 2002, 168:2963-2969.
66. Benacerraf B., Sebestyen M.M., Schlossman S. A quantitative study of the kinetics of blood clearance of P32-labelled Escherichia coli and Staphylococci by the reticuloendothelial system. J. Exp. Med. 1959, 110:27-48.
67. Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology 2009, 50:638-644.
68. Rao R.K., Seth A., Sheth P. Recent Advances in Alcoholic Liver Disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286:G881-G884.
69. Mimura Y., Sakisaka S., Harada M., Sata M., Tanikawa K. Role of hepatocytes in direct clearance of lipopolysaccharide in rats. Gastroenterology 1995, 109:1969-1976.
70. Medvedev A.E., Sabroe I., Hasday J.D., Vogel S.N. Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease. J. Endotoxin Res. 2006, 12:133-150.
71. Schuchmann M., Hermann F., Herkel J., van der Zee R., Galle P.R., Lohse A.W. HSP60 and CpG-DNA-oligonucleotides differentially regulate LPS-tolerance of hepatic Kupffer cells. Immunol. Lett. 2004, 93:199-204.
72. Enomoto N., Ikejima K., Bradford B., Rivera C., Kono H., Brenner D.A., Thurman R.G. Alcohol causes both tolerance and sensitization of rat Kupffer cells via mechanisms dependent on endotoxin. Gastroenterology 1998, 115:443-451.
73. Miura K., Kodama Y., Inokuchi S., Schnabl B., Aoyama T., Ohnishi H., Olefsky J.M., Brenner D.A., Seki E. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010, 139. 323.e7-334.e7.
74. Vijay-Kumar M., Aitken J.D., Carvalho F.A., Cullender T.C., Mwangi S., Srinivasan S., Sitaraman S.V., Knight R., Ley R.E., Gewirtz A.T. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
75. Yajima S., Morisaki H., Serita R., Suzuki T., Katori N., Asahara T., Nomoto K., Kobayashi F., Ishizaka A., Takeda J. Tumor necrosis factor-alpha mediates hyperglycemia-augmented gut barrier dysfunction in endotoxemia. Crit. Care Med. 2009, 37:1024-1030.
76. Cani P.D., Bibiloni R., Knauf C., Waget A., Neyrinck A.M., Delzenne N.M., Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57:1470-1481.
77. Ley R.E., Backhed F., Turnbaugh P., Lozupone C.A., Knight R.D., Gordon J.I. Obesity alters gut microbial ecology. Proc. Natl. Acad. Sci. USA. 2005, 102:11070-11075.
78. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
79. Bode C., Bode J.C. Effect of alcohol consumption on the gut. Best Pract. Res. Clin. Gastroenterol. 2003, 17:575-592.
80. Enomoto N., Ikejima K., Yamashina S., Hirose M., Shimizu H., Kitamura T., Takei Y., Sato And N., Thurman R.G. Kupffer cell sensitization by alcohol involves increased permeability to gut-derived endotoxin. Alcohol. Clin. Exp. Res. 2001, 25:51S-54S.
81. Bjarnason I., Peters T.J., Wise R.J. The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet 1984, 1:179-182.
82. Adachi Y., Moore L.E., Bradford B.U., Gao W., Thurman R.G. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995, 108:218-224.
83. Connolly M.K., Bedrosian A.S., Mallen-St Clair J., Mitchell A.P., Ibrahim J., Stroud A., Pachter H.L., Bar-Sagi D., Frey A.B., Miller G. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J. Clin. Invest. 2009, 119:3213-3225.
84. Bergheim I., Weber S., Vos M., Kramer S., Volynets V., Kaserouni S., McClain C.J., Bischoff S.C. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J. Hepatol. 2008, 48:983-992.
85. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., Frees K., Watt J.L., Schwartz D.A. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 2000, 25:187-191.
86. Yin M., Bradford B.U., Wheeler M.D., Uesugi T., Froh M., Goyert S.M., Thurman R.G. Reduced early alcohol-induced liver injury in CD14-deficient mice. J. Immunol. 2001, 166:4737-4742.
87. Szabo G., Dolganiuc A., Mandrekar P. Pattern recognition receptors: a contemporary view on liver diseases. Hepatology 2006, 44:287-298.
88. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J. Hepatol. 2009, 51:212-223.
89. Dolganiuc A., Kodys K., Kopasz A., Marshall C., Do T., Romics L., Mandrekar P., Zapp M., Szabo G. Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J. Immunol. 2003, 170:5615-5624.
90. Dolganiuc A., Norkina O., Kodys K., Catalano D., Bakis G., Marshall C., Mandrekar P., Szabo G. Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. Gastroenterology 2007, 133:1627-1636.
91. Seki E., De Minicis S., Gwak G.Y., Kluwe J., Inokuchi S., Bursill C.A., Llovet J.M., Brenner D.A., Schwabe R.F. CCR1 and CCR5 promote hepatic fibrosis in mice. J. Clin. Invest. 2009, 119:1858-1870.
92. Seki E., de Minicis S., Inokuchi S., Taura K., Miyai K., van Rooijen N., Schwabe R.F., Brenner D.A. CCR2 promotes hepatic fibrosis in mice. Hepatology 2009, 50:185-197.
93. Rehm J., Room R., Monteiro M., Gmel G., Graham K., Rehn N., Sempos C.T., Jernigan D. Alcohol as a risk factor for global burden of disease. Eur. Addict. Res. 2003, 9:157-164.
94. Mills S.J., Harrison S.A. Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease. Curr. Gastroenterol. Rep. 2005, 7:32-36.
95. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 2000, 275:2247-2250.
96. Staun-Olsen P., Bjorneboe M., Prytz H., Thomsen A.C., Orskov F. Escherichia coli antibodies in alcoholic liver disease. Correlation to alcohol consumption, alcoholic hepatitis, and serum IgA. Scand. J. Gastroenterol. 1983, 18:889-896.
97. Duerkop B.A., Vaishnava S., Hooper L.V. Immune responses to the microbiota at the intestinal mucosal surface. Immunity 2009, 31:368-376.
98. Roth J., McClellan J.L., Kluger M.J., Zeisberger E. Attenuation of fever and release of cytokines after repeated injections of lipopolysaccharide in guinea-pigs. J. Physiol. 1994, 477(Pt 1):177-185.
99. Nanji A.A., Jokelainen K., Fotouhinia M., Rahemtulla A., Thomas P., Tipoe G.L., Su G.L., Dannenberg A.J. Increased severity of alcoholic liver injury in female rats: role of oxidative stress, endotoxin, and chemokines. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 281:G1348-G1356.
100. Fukui H., Brauner B., Bode J.C., Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J. Hepatol. 1991, 12:162-169.
101. Nanji A.A., Khettry U., Sadrzadeh S.M. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc. Soc. Exp. Biol. Med. 1994, 205:243-247.
102. Tang Y., Banan A., Forsyth C.B., Fields J.Z., Lau C.K., Zhang L.J., Keshavarzian A. Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease. Alcohol. Clin. Exp. Res. 2008, 32:355-364.
103. Naito M., Hasegawa G., Ebe Y., Yamamoto T. Differentiation and function of Kupffer cells. Med. Electron Microsc. 2004, 37:16-28.
104. Thurman R.G. II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am. J. Physiol. 1998, 275:G605-G611.
105. Inokuchi S., Tsukamoto H., Park E., Liu Z.X., Brenner D.A., Seki E. Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice. Alcohol. Clin. Exp. Res. 2011, 35:1509-1518.
106. Yin M., Wheeler M.D., Kono H., Bradford B.U., Gallucci R.M., Luster M.I., Thurman R.G. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999, 117:942-952.
107. Ferrero E., Jiao D., Tsuberi B.Z., Tesio L., Rong G.W., Haziot A., Goyert S.M. Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. Proc. Natl. Acad. Sci. USA. 1993, 90:2380-2384.
108. Frances R., Benlloch S., Zapater P., Gonzalez J.M., Lozano B., Munoz C., Pascual S., Casellas J.A., Uceda F., Palazon J.M., et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology 2004, 39:484-491.
109. Such J., Frances R., Munoz C., Zapater P., Casellas J.A., Cifuentes A., Rodriguez-Valera F., Pascual S., Sola-Vera J., Carnicer F., et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002, 36:135-141.
110. Romics L., Dolganiuc A., Velayudham A., Kodys K., Mandrekar P., Golenbock D., Kurt-Jones E., Szabo G. Toll-like receptor 2 mediates inflammatory cytokine induction but not sensitization for liver injury by Propioni- bacterium acnes. J. Leukoc. Biol. 2005, 78:1255-1264.
111. Gustot T., Lemmers A., Moreno C., Nagy N., Quertinmont E., Nicaise C., Franchimont D., Louis H., Deviere J., Le Moine O. Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology 2006, 43:989-1000.
112. Massonnet B., Delwail A., Ayrault J.M., Chagneau-Derrode C., Lecron J.C., Silvain C. Increased immunoglobulin A in alcoholic liver cirrhosis: exploring the response of B cells to Toll-like receptor 9 activation. Clin. Exp. Immunol. 2009, 158:115-124.
113. Stadlbauer V., Mookerjee R.P., Wright G.A., Davies N.A., Jurgens G., Hallstrom S., Jalan R. Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296:G15-G22.
114. Malhi H., Barreyro F.J., Isomoto H., Bronk S.F., Gores G.J. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut 2007, 56:1124-1131.
115. Kendrick S.F., O'Boyle G., Mann J., Zeybel M., Palmer J., Jones D.E., Day C.P. Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis. Hepatology 2010, 51:1988-1997.
116. Roychowdhury S., McMullen M.R., Pritchard M.T., Hise A.G., van Rooijen N., Medof M.E., Stavitsky A.B., Nagy L.E. An early complement-dependent and TLR-4-independent phase in the pathogenesis of ethanol-induced liver injury in mice. Hepatology 2009, 49:1326-1334.
117. Hritz I., Mandrekar P., Velayudham A., Catalano D., Dolganiuc A., Kodys K., Kurt-Jones E., Szabo G. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology 2008, 48:1224-1231.
118. Petrasek J., Dolganiuc A., Csak T., Nath B., Hritz I., Kodys K., Catalano D., Kurt-Jones E., Mandrekar P., Szabo G. Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells. Hepatology 2011, 53:649-660.
119. Morin P., Braganca J., Bandu M.T., Lin R., Hiscott J., Doly J., Civas A. Preferential binding sites for interferon regulatory factors 3 and 7 involved in interferon-A gene transcription. J. Mol. Biol. 2002, 316:1009-1022.
120. Zhao X.J., Dong Q., Bindas J., Piganelli J.D., Magill A., Reiser J., Kolls J.K. TRIF and IRF-3 binding to the TNF promoter results in macrophage TNF dysregulation and steatosis induced by chronic ethanol. J. Immunol. 2008, 181:3049-3056.
121. Mosser D.M., Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol. Rev. 2008, 226:205-218.
122. Mandrekar P., Szabo G. Signalling pathways in alcohol-induced liver inflammation. J. Hepatol. 2009, 50:1258-1266.
123. Baldwin A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 1996, 14:649-683.
124. Ghosh S., May M.J., Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 1998, 16:225-260.
125. Yeligar S.M., Machida K., Tsukamoto H., Kalra V.K. Ethanol augments RANTES/CCL5 expression in rat liver sinusoidal endothelial cells and human endothelial cells via activation of NF-kappa B, HIF-1 alpha, and AP-1. J. Immunol. 2009, 183:5964-5976.
126. Shi L., Kishore R., McMullen M.R., Nagy L.E. Chronic ethanol increases lipopolysaccharide-stimulated Egr-1 expression in RAW 264.7 macrophages: contribution to enhanced tumor necrosis factor alpha production. J. Biol. Chem. 2002, 277:14777-14785.
127. McMullen M.R., Pritchard M.T., Wang Q., Millward C.A., Croniger C.M., Nagy L.E. Early growth response-1 transcription factor is essential for ethanol-induced fatty liver injury in mice. Gastroenterology 2005, 128:2066-2076.
128. Li J., French B., Wu Y., Vanketesh R., Montgomery R., Bardag-Gorce F., Kitto J., French S.W. Liver hypoxia and lack of recovery after reperfusion at high blood alcohol levels in the intragastric feeding model of alcohol liver disease. Exp. Mol. Pathol. 2004, 77:184-192.
129. Nath B., Levin I., Csak T., Petrasek J., Mueller C., Kodys K., Catalano D., Mandrekar P., Szabo G. Hepatocyte-specific hypoxia-inducible factor-1alpha is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice. Hepatology 2011, 53:1526-1537.
130. Motomura W., Inoue M., Ohtake T., Takahashi N., Nagamine M., Tanno S., Kohgo Y., Okumura T. Up-regulation of ADRP in fatty liver in human and liver steatosis in mice fed with high fat diet. Biochem. Biophys. Res. Commun. 2006, 340:1111-1118.
131. Chang B.H., Li L., Paul A., Taniguchi S., Nannegari V., Heird W.C., Chan L. Protection against fatty liver but normal adipogenesis in mice lacking adipose differentiation-related protein. Mol. Cell. Biol. 2006, 26:1063-1076.
132. Clement S., Juge-Aubry C., Sgroi A., Conzelmann S., Pazienza V., Pittet-Cuenod B., Meier C.A., Negro F. Monocyte chemoattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes. Hepatology 2008, 48:799-807.
133. Apte U.M., Banerjee A., McRee R., Wellberg E., Ramaiah S.K. Role of osteopontin in hepatic neutrophil infiltration during alcoholic steatohepatitis. Toxicol. Appl. Pharmacol. 2005, 207:25-38.
134. Ramaiah S.K., Jaeschke H. Hepatic neutrophil infiltration in the pathogenesis of alcohol-induced liver injury. Toxicol. Mech. Methods 2007, 17:431-440.
135. McClain C.J., Barve S., Deaciuc I., Kugelmas M., Hill D. Cytokines in alcoholic liver disease. Semin. Liver Dis. 1999, 19:205-219.
136. Marcos M., Gomez-Munuera M., Pastor I., Gonzalez-Sarmiento R., Laso F.J. Tumor necrosis factor polymorphisms and alcoholic liver disease: a HuGE review and meta-analysis. Am. J. Epidemiol. 2009, 170:948-956.
137. Petrasek J., Hubacek J.A., Stickel F., Sperl J., Berg T., Ruf E., Wichmann H.E., Pfeufer A., Meitinger T., Trunecka P., et al. Do common genetic variants in endotoxin signaling pathway contribute to predisposition to alcoholic liver cirrhosis?. Clin. Chem. Lab. Med. 2009, 47:398-404.
138. Bala S., Marcos M., Kodys K., Csak T., Catalano D., Mandrekar P., Szabo G. Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor alpha (TNF{alpha}) production via increased mRNA half-life in alcoholic liver disease. J. Biol. Chem. 2011, 286:1436-1444.
139. Chen G., Goeddel D.V. TNF-R1 signaling: a beautiful pathway. Science 2002, 296:1634-1635.
140. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
141. Wilson N.S., Dixit V., Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat. Immunol. 2009, 10:348-355.
142. Pastorino J.G., Hoek J.B. Ethanol potentiates tumor necrosis factor-alpha cytotoxicity in hepatoma cells and primary rat hepatocytes by promoting induction of the mitochondrial permeability transition. Hepatology 2000, 31:1141-1152.
143. Cahill A., Stabley G.J., Wang X., Hoek J.B. Chronic ethanol consumption causes alterations in the structural integrity of mitochondrial DNA in aged rats. Hepatology 1999, 30:881-888.
144. Colell A., Garcia-Ruiz C., Miranda M., Ardite E., Mari M., Morales A., Corrales F., Kaplowitz N., Fernandez-Checa J.C. Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Gastroenterology 1998, 115:1541-1551.
145. Song Z., Zhou Z., Song M., Uriarte S., Chen T., Deaciuc I., McClain C.J. Alcohol-induced S-adenosylhomocysteine accumulation in the liver sensitizes to TNF hepatotoxicity: possible involvement of mitochondrial S-adenosylmethionine transport. Biochem. Pharmacol. 2007, 74:521-531.
146. Purohit V., Gao B., Song B.J. Molecular mechanisms of alcoholic fatty liver. Alcohol. Clin. Exp. Res. 2009, 33:191-205.
147. Enomoto N., Ikejima K., Yamashina S., Enomoto A., Nishiura T., Nishimura T., Brenner D.A., Schemmer P., Bradford B.U., Rivera C.A., et al. Kupffer cell-derived prostaglandin E(2) is involved in alcohol-induced fat accumulation in rat liver. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 279:G100-G106.
148. Lawler J.F., Yin M., Diehl A.M., Roberts E., Chatterjee S. Tumor necrosis factor-alpha stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase. J. Biol. Chem. 1998, 273:5053-5059.
149. Raetzsch C.F., Brooks N.L., Alderman J.M., Moore K.S., Hosick P.A., Klebanov S., Akira S., Bear J.E., Baldwin A.S., Mackman N., et al. Lipopolysaccharide inhibition of glucose production through the Toll-like receptor-4, myeloid differentiation factor 88, and nuclear factor kappa b pathway. Hepatology 2009, 50:592-600.
150. Berg D.J., Kuhn R., Rajewsky K., Muller W., Menon S., Davidson N., Grunig G., Rennick D. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J. Clin. Invest. 1995, 96:2339-2347.
151. Miller A.M., Wang H., Bertola A., Park O., Horiguchi N., Ki S.H., Yin S., Lafdil F., Gao B. Inflammation-associated IL-6/STAT3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in IL-10 deficient mice. Hepatology 2011, 54:846-856.
152. Tanaka Y., Takahashi A., Watanabe K., Takayama K., Yahata T., Habu S., Nishimura T. A pivotal role of IL-12 in Th1-dependent mouse liver injury. Int. Immunol. 1996, 8:569-576.
153. Car B.D., Eng V.M., Schnyder B., Ozmen L., Huang S., Gallay P., Heumann D., Aguet M., Ryffel B. Interferon gamma receptor deficient mice are resistant to endotoxic shock. J. Exp. Med. 1994, 179:1437-1444.
154. Sakao Y., Takeda K., Tsutsui H., Kaisho T., Nomura F., Okamura H., Nakanishi K., Akira S. IL-18-deficient mice are resistant to endotoxin-induced liver injury but highly susceptible to endotoxin shock. Int. Immunol. 1999, 11:471-480.
155. Cosgrove B.D., Cheng C., Pritchard J.R., Stolz D.B., Lauffenburger D.A., Griffith L.G. An inducible autocrine cascade regulates rat hepatocyte proliferation and apoptosis responses to tumor necrosis factor-alpha. Hepatology 2008, 48:276-288.
156. Petrasek J., Dolganiuc A., Csak T., Kurt-Jones E.A., Szabo G. Type I interferons protect from Toll-like receptor 9-associated liver injury and regulate IL-1 receptor antagonist in mice. Gastroenterology 2011, 140:697-708.e4.
157. Afford S.C., Fisher N.C., Neil D.A., Fear J., Brun P., Hubscher S.G., Adams D.H. Distinct patterns of chemokine expression are associated with leukocyte recruitment in alcoholic hepatitis and alcoholic cirrhosis. J. Pathol. 1998, 186:82-89.
158. Mandrekar P., Ambade A., Lim A., Szabo G., Catalano D. An essential role for MCP-1 in alcoholic liver injury: regulation of pro-inflammatory cytokines and hepatic steatosis. Hepatology 2011, 54:2185-2197.
159. Feldstein A.E., Bailey S.M. Emerging role of redox dysregulation in alcoholic and nonalcoholic fatty liver disease. Antioxid. Redox Signal. 2011, 15:421-424.
160. Morris E.M., Rector R.S., Thyfault J.P., Ibdah J.A. Mitochondria and redox signaling in steatohepatitis. Antioxid. Redox Signal. 2011, 15:485-504.
161. Perez M.J., Cederbaum A.I. Adenovirus-mediated expression of Cu/Zn- or Mn-superoxide dismutase protects against CYP2E1-dependent toxicity. Hepatology 2003, 38:1146-1158.
162. Bailey S.M., Patel V.B., Young T.A., Asayama K., Cunningham C.C. Chronic ethanol consumption alters the glutathione/glutathione peroxidase-1 system and protein oxidation status in rat liver. Alcohol. Clin. Exp. Res. 2001, 25:726-733.
163. Yang E.S., Lee J.H., Park J.W. Ethanol induces peroxynitrite-mediated toxicity through inactivation of NADP+-dependent isocitrate dehydrogenase and superoxide dismutase. Biochimie 2008, 90:1316-1324.
164. Wheeler M.D., Kono H., Yin M., Rusyn I., Froh M., Connor H.D., Mason R.P., Samulski R.J., Thurman R.G. Delivery of the Cu/Zn-superoxide dismutase gene with adenovirus reduces early alcohol-induced liver injury in rats. Gastroenterology 2001, 120:1241-1250.
165. Wheeler M.D., Nakagami M., Bradford B.U., Uesugi T., Mason R.P., Connor H.D., Dikalova A., Kadiiska M., Thurman R.G. Overexpression of manganese superoxide dismutase prevents alcohol-induced liver injury in the rat. J. Biol. Chem. 2001, 276:36664-36672.
166. Kono H., Rusyn I., Yin M., Gabele E., Yamashina S., Dikalova A., Kadiiska M.B., Connor H.D., Mason R.P., Segal B.H., et al. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J. Clin. Invest. 2000, 106:867-872.
167. Park H.S., Jung H.Y., Park E.Y., Kim J., Lee W.J., Bae Y.S. Cutting edge: direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-kappa B. J. Immunol. 2004, 173:3589-3593.
168. Dasu M.R., Devaraj S., Zhao L., Hwang D.H., Jialal I. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 2008, 57:3090-3098.
169. Levin I., Petrasek J., Szabo G. The presence of p47phox in liver parenchymal cells is a key mediator in the pathogenesis of alcoholic liver steatosis. Alcohol. Clin. Exp. Res. 2012, 36:1397-1406. 10.1111/j.1530-0277.2012.01739.x.
170. De Minicis S., Seki E., Paik Y.H., Osterreicher C.H., Kodama Y., Kluwe J., Torozzi L., Miyai K., Benedetti A., Schwabe R.F., et al. Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibrosis. Hepatology 2010, 52:1420-1430.
171. Tiniakos D.G., Vos M.B., Brunt E.M. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu. Rev. Pathol. 2010, 5:145-171.
172. Bedogni G., Miglioli L., Masutti F., Tiribelli C., Marchesini G., Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005, 42:44-52.
173. Siddique A., Kowdley K.V. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin. Liver Dis. 2011, 15:281-296.
174. Li Z., Yang S., Lin H., Huang J., Watkins P.A., Moser A.B., Desimone C., Song X.Y., Diehl A.M. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37:343-350.
175. Day C.P., James O.F. Steatohepatitis: a tale of two "hits" ?. Gastroenterology 1998, 114:842-845.
176. Csak T., Ganz M., Pespisa J., Kodys K., Dolganiuc A., Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011, 54:133-144.
177. Wigg A.J., Roberts-Thomson I.C., Dymock R.B., McCarthy P.J., Grose R.H., Cummins A.G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48:206-211.
178. Rivera C.A., Adegboyega P., van Rooijen N., Tagalicud A., Allman M., Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 2007, 47:571-579.
179. Brun P., Castagliuolo I., Di Leo V., Buda A., Pinzani M., Palu G., Martines D. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292:G518-G525.
180. Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
181. Cani P.D., Amar J., Iglesias M.A., Poggi M., Knauf C., Bastelica D., Neyrinck A.M., Fava F., Tuohy K.M., Chabo C., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
182. Solga S.F., Diehl A.M. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J. Hepatol. 2003, 38:681-687.
183. Velayudham A., Dolganiuc A., Ellis M., Petrasek J., Kodys K., Mandrekar P., Szabo G. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009, 49:989-997.
184. Csak T., Velayudham A., Hritz I., Petrasek J., Levin I., Lippai D., Catalano D., Mandrekar P., Dolganiuc A., Kurt-Jones E., et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 300:G433-G441.
185. Romics L., Mandrekar P., Kodys K., Velayudham A., Drechsler Y., Dolganiuc A., Szabo G. Increased lipopolysaccharide sensitivity in alcoholic fatty livers is independent of leptin deficiency and toll-like receptor 4 (TLR4) or TLR2 mRNA expression. Alcohol. Clin. Exp. Res. 2005, 29:1018-1026.
186. Yang S.Q., Lin H.Z., Lane M.D., Clemens M., Diehl A.M. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc. Natl. Acad. Sci. USA. 1997, 94:2557-2562.
187. Spruss A., Kanuri G., Wagnerberger S., Haub S., Bischoff S.C., Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 2009, 50:1094-1104.
188. Miura K., Seki E., Ohnishi H., Brenner D.A. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic Fatty liver disease. Gastroenterol. Res. Pract. 2010, 2010:362847.
189. Watanabe A., Hashmi A., Gomes D.A., Town T., Badou A., Flavell R.A., Mehal W.Z. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007, 46:1509-1518.
190. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 2006, 116:3015-3025.
191. Senn J.J. Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J. Biol. Chem. 2006, 281:26865-26875.
192. Erridge C., Samani N.J. Saturated fatty acids do not directly stimulate Toll-like receptor signaling. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1944-1949.
193. Li L., Chen L., Hu L., Liu Y., Sun H.Y., Tang J., Hou Y.J., Chang Y.X., Tu Q.Q., Feng G.S., et al. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 2011, 54:1620-1630.
194. Wang Z., Choi M.K., Ban T., Yanai H., Negishi H., Lu Y., Tamura T., Takaoka A., Nishikura K., Taniguchi T. Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc. Natl. Acad. Sci. USA. 2008, 105:5477-5482.
195. Day C.P. From fat to inflammation. Gastroenterology 2006, 130:207-210.
196. Feldstein A.E., Werneburg N.W., Canbay A., Guicciardi M.E., Bronk S.F., Rydzewski R., Burgart L.J., Gores G.J. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004, 40:185-194.
197. Malhi H., Gores G.J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin. Liver Dis. 2008, 28:360-369.
198. Malhi H., Bronk S.F., Werneburg N.W., Gores G.J. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J. Biol. Chem. 2006, 281:12093-12101.
199. Feldstein A.E., Canbay A., Angulo P., Taniai M., Burgart L.J., Lindor K.D., Gores G.J. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125:437-443.
200. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005, 115:1343-1351.
201. Crabb D.W., Liangpunsakul S. Alcohol and lipid metabolism. J. Gastroenterol. Hepatol. 2006, 21(Suppl. 3):S56-S60.
202. Malhi H., Gores G.J. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008, 134:1641-1654.
203. Musso G., Gambino R., Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog. Lipid Res. 2009, 48:1-26.
204. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52:1836-1846.
205. Vandanmagsar B., Youm Y.H., Ravussin A., Galgani J.E., Stadler K., Mynatt R.L., Ravussin E., Stephens J.M., Dixit V.D. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 2011, 17:179-188.
206. Kamari Y., Shaish A., Vax E., Shemesh S., Kandel-Kfir M., Arbel Y., Olteanu S., Barshack I., Dotan S., Voronov E., et al. Lack of interleukin-1alpha or interleukin-1beta inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J. Hepatol. 2011, 55:1086-1094.
207. Wen H., Gris D., Lei Y., Jha S., Zhang L., Huang M.T., Brickey W.J., Ting J.P. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 2011, 12:408-415.
208. Stienstra R., Saudale F., Duval C., Keshtkar S., Groener J.E., van Rooijen N., Staels B., Kersten S., Muller M. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology 2010, 51:511-522.
209. Stienstra R., van Diepen J.A., Tack C.J., Zaki M.H., van de Veerdonk F.L., Perera D., Neale G.A., Hooiveld G.J., Hijmans A., Vroegrijk I., et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc. Natl. Acad. Sci. USA. 2011, 108:15324-15329.
210. Martinon F., Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 2007, 14:10-22.
211. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
212. Cayrol C., Girard J.P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:9021-9026.
213. Netea M.G., Nold-Petry C.A., Nold M.F., Joosten L.A., Opitz B., van der Meer J.H., van de Veerdonk F.L., Ferwerda G., Heinhuis B., Devesa I., et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009, 113:2324-2335.
214. Kummer J.A., Broekhuizen R., Everett H., Agostini L., Kuijk L., Martinon F., van Bruggen R., Tschopp J. Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response. J. Histochem. Cytochem. 2007, 55:443-452.
215. Csak T., Dolganiuc A., Kodys K., Nath B., Petrasek J., Bala S., Lippai D., Szabo G. Mitochondrial antiviral signaling protein defect links impaired antiviral response and liver injury in steatohepatitis in mice. Hepatology 2011, 53:1917-1931.
216. Cazanave S.C., Gores G.J. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin. Lipidol. 2010, 5:71-85.
217. Ji J., Zhang L., Wang P., Mu Y.M., Zhu X.Y., Wu Y.Y., Yu H., Zhang B., Chen S.M., Sun X.Z. Saturated free fatty acid, palmitic acid, induces apoptosis in fetal hepatocytes in culture. Exp. Toxicol. Pathol. 2005, 56:369-376.
218. Ricchi M., Odoardi M.R., Carulli L., Anzivino C., Ballestri S., Pinetti A., Fantoni L.I., Marra F., Bertolotti M., Banni S., et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J. Gastroenterol. Hepatol. 2009, 24:830-840.
219. Bosch F.X., Ribes J., Diaz M., Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
220. Aoyama T., Paik Y.H., Seki E. Toll-like receptor signaling and liver fibrosis. Gastroenterol. Res. Pract. 2010, 2010. 192543 (Epub 2010 Jul 25).
221. Nolan J.P., Leibowitz A.I. Endotoxins in liver disease. Gastroenterology 1978, 75:765-766.
222. Grinko I., Geerts A., Wisse E. Experimental biliary fibrosis correlates with increased numbers of fat-storing and Kupffer cells, and portal endotoxemia. J. Hepatol. 1995, 23:449-458.
223. Lin R.S., Lee F.Y., Lee S.D., Tsai Y.T., Lin H.C., Lu R.H., Hsu W.C., Huang C.C., Wang S.S., Lo K.J. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J. Hepatol. 1995, 22:165-172.
224. Chan C.C., Hwang S.J., Lee F.Y., Wang S.S., Chang F.Y., Li C.P., Chu C.J., Lu R.H., Lee S.D. Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scand. J. Gastroenterol. 1997, 32:942-946.
225. Greenwel P., Dominguez-Rosales J.A., Mavi G., Rivas-Estilla A.M., Rojkind M. Hydrogen peroxide: a link between acetaldehyde-elicited alpha1(I) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells. Hepatology 2000, 31:109-116.
226. Nieto N., Friedman S.L., Cederbaum A.I. Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. J. Biol. Chem. 2002, 277:9853-9864.
227. Svegliati-Baroni G., Inagaki Y., Rincon-Sanchez A.R., Else C., Saccomanno S., Benedetti A., Ramirez F., Rojkind M. Early response of alpha2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-beta independent. Hepatology 2005, 42:343-352.
228. Canbay A., Feldstein A.E., Higuchi H., Werneburg N., Grambihler A., Bronk S.F., Gores G.J. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003, 38:1188-1198.
229. Purohit V., Russo D. Cellular and molecular mechanisms of alcoholic hepatitis: introduction and summary of the symposium. Alcohol 2002, 27:3-6.
230. Matsuoka M., Tsukamoto H. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: implication for a pathogenetic role in alcoholic liver fibrogenesis. Hepatology 1990, 11:599-605.
231. Jeong W.I., Gao B. Innate immunity and alcoholic liver fibrosis. J. Gastroenterol. Hepatol. 2008, 23(Suppl. 1):S112-S118.
232. Marra F., Aleffi S., Galastri S., Provenzano A. Mononuclear cells in liver fibrosis. Semin. Immunopathol. 2009, 31:345-358.
233. Paik Y.H., Schwabe R.F., Bataller R., Russo M.P., Jobin C., Brenner D.A. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003, 37:1043-1055.
234. Luedde T., Trautwein C. A molecular link between inflammation and fibrogenesis: the bacterial microflora influences hepatic fibrosis via toll-like receptor 4-dependent modification of transforming growth factor-beta signaling in hepatic stellate cells. Hepatology 2008, 47:1089-1091.
235. Casey C.A., Nanji A., Cederbaum A.I., Adachi M., Takahashi T. Alcoholic liver disease and apoptosis. Alcohol. Clin. Exp. Res. 2001, 25:49S-53S.
236. Kawai T., Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 2009, 21:317-337.
237. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
238. Kodama Y., Kisseleva T., Iwaisako K., Miura K., Taura K., De Minicis S., Osterreicher C.H., Schnabl B., Seki E., Brenner D.A. c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology 2009, 137:1467-1477.e5.
239. Brenner D.A., Seki E., Taura K., Kisseleva T., Deminicis S., Iwaisako K., Inokuchi S., Schnabl B., Oesterreicher C.H., Paik Y.H., et al. Non-alcoholic steatohepatitis-induced fibrosis: toll-like receptors, reactive oxygen species and Jun N-terminal kinase. Hepatol. Res. 2011, 41:683-686.
240. Siu L., Foont J., Wands J.R. Hepatitis C virus and alcohol. Semin. Liver Dis. 2009, 29:188-199.
241. Piasecki B.A., Lewis J.D., Reddy K.R., Bellamy S.L., Porter S.B., Weinrieb R.M., Stieritz D.D., Chang K.M. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology 2004, 40:892-899.
242. Aloman C., Gehring S., Wintermeyer P., Kuzushita N., Wands J.R. Chronic ethanol consumption impairs cellular immune responses against HCV NS5 protein due to dendritic cell dysfunction. Gastroenterology 2007, 132:698-708.
243. Szabo G., Wands J.R., Eken A., Osna N.A., Weinman S.A., Machida K., Joe Wang H. Alcohol and hepatitis C virus-interactions in immune dysfunctions and liver damage. Alcohol. Clin. Exp. Res. 2010, 34:1675-1686.
244. Goldberg A.L., Cascio P., Saric T., Rock K.L. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol. Immunol. 2002, 39:147-164.
245. Osna N.A., Haorah J., Krutik V.M., Donohue T.M. Peroxynitrite alters the catalytic activity of rodent liver proteasome in vitro and in vivo. Hepatology 2004, 40:574-582.
246. Korenaga M., Wang T., Li Y., Showalter L.A., Chan T., Sun J., Weinman S.A. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J. Biol. Chem. 2005, 280:37481-37488.
247. Otani K., Korenaga M., Beard M.R., Li K., Qian T., Showalter L.A., Singh A.K., Wang T., Weinman S.A. Hepatitis C virus core protein, cytochrome P450 2E1, and alcohol produce combined mitochondrial injury and cytotoxicity in hepatoma cells. Gastroenterology 2005, 128:96-107.
248. Hassan M.M., Hwang L.Y., Hatten C.J., Swaim M., Li D., Abbruzzese J.L., Beasley P., Patt Y.Z. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002, 36:1206-1213.
249. Fattovich G., Stroffolini T., Zagni I., Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127:S35-S50.
250. Yuan J.M., Govindarajan S., Arakawa K., Yu M.C. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the US. Cancer 2004, 101:1009-1017.
251. Moriya K., Nakagawa K., Santa T., Shintani Y., Fujie H., Miyoshi H., Tsutsumi T., Miyazawa T., Ishibashi K., Horie T., et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res. 2001, 61:4365-4370.
252. Perlemuter G., Sabile A., Letteron P., Vona G., Topilco A., Chretien Y., Koike K., Pessayre D., Chapman J., Barba G., et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 2002, 16:185-194.
253. Kawaguchi T., Yoshida T., Harada M., Hisamoto T., Nagao Y., Ide T., Taniguchi E., Kumemura H., Hanada S., Maeyama M., et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am. J. Pathol. 2004, 165:1499-1508.
254. Koike K., Tsutsumi T., Miyoshi H., Shinzawa S., Shintani Y., Fujie H., Yotsuyanagi H., Moriya K. Molecular basis for the synergy between alcohol and hepatitis C virus in hepatocarcinogenesis. J. Gastroenterol. Hepatol. 2008, 23(Suppl 1):S87-S91.
255. French S.W., Oliva J., French B.A., Li J., Bardag-Gorce F. Alcohol, nutrition and liver cancer: role of Toll-like receptor signaling. World J. Gastroenterol. 2010, 16:1344-1348.
256. Machida K., Liu J., Jeong H., Mishra L., Tsukamoto H. TLR4-dependent Nanog+ cancer stem cells exhibit defective TGF-beta signaling. Hepatology 2009, 50(Suppl.):A871.
257. Tang Y., Kitisin K., Jogunoori W., Li C., Deng C.X., Mueller S.C., Ressom H.W., Rashid A., He A.R., Mendelson J.S., et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc. Natl. Acad. Sci. USA. 2008, 105:2445-2450.
258. Bellentani S., Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann. Hepatol. 2009, 8(Suppl 1):S4-S8.
259. Younossi Z.M., McCullough A.J. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int. 2009, 29(Suppl. 2):3-12.
260. Hui J.M., Sud A., Farrell G.C., Bandara P., Byth K., Kench J.G., McCaughan G.W., George J. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003, 125:1695-1704.
261. Tang E.D., Wang C.Y. MAVS self-association mediates antiviral innate immune signaling. J. Virol. 2009, 83:3420-3428.
262. Seth R.B., Sun L., Ea C.K., Chen Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005, 122:669-682.
263. Wei Y., Rector R.S., Thyfault J.P., Ibdah J.A. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J. Gastroenterol. 2008, 14:193-199.
264. Caroppi P., Sinibaldi F., Fiorucci L., Santucci R. Apoptosis and human diseases: mitochondrion damage and lethal role of released cytochrome C as proapoptotic protein. Curr. Med. Chem. 2009, 16:4058-4065.
265. Kirpich I.A., Solovieva N.V., Leikhter S.N., Shidakova N.A., Lebedeva O.V., Sidorov P.I., Bazhukova T.A., Soloviev A.G., Barve S.S., McClain C.J., et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008, 42:675-682.
266. Stadlbauer V., Mookerjee R.P., Hodges S., Wright G.A., Davies N.A., Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J. Hepatol. 2008, 48:945-951.
267. Pappas S.C. Good science behind hepatitis C virus antiviral drug development: necessary but not sufficient. Hepatology 2007, 46:1317-1318.
268. McHutchison J.G., Bacon B.R., Gordon S.C., Lawitz E., Shiffman M., Afdhal N.H., Jacobson I.M., Muir A., Al-Adhami M., Morris M.L., et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 2007, 46:1341-1349.
269. Horsmans Y., Berg T., Desager J.P., Mueller T., Schott E., Fletcher S.P., Steffy K.R., Bauman L.A., Kerr B.M., Averett D.R. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005, 42:724-731.
270. Kim H.M., Park B.S., Kim J.I., Kim S.E., Lee J., Oh S.C., Enkhbayar P., Matsushima N., Lee H., Yoo O.J., et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 2007, 130:906-917.
271. Fort M.M., Mozaffarian A., Stover A.G., Correia Jda S., Johnson D.A., Crane R.T., Ulevitch R.J., Persing D.H., Bielefeldt-Ohmann H., Probst P., et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J. Immunol. 2005, 174:6416-6423.
272. Spahr L., Rubbia-Brandt L., Frossard J.L., Giostra E., Rougemont A.L., Pugin J., Fischer M., Egger H., Hadengue A. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J. Hepatol. 2002, 37:448-455.
273. Mookerjee R.P., Sen S., Davies N.A., Hodges S.J., Williams R., Jalan R. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 2003, 52:1182-1187.
274. Naveau S., Chollet-Martin S., Dharancy S., Mathurin P., Jouet P., Piquet M.A., Davion T., Oberti F., Broet P., Emilie D., et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004, 39:1390-1397.
275. Lucey M.R., Mathurin P., Morgan T.R. Alcoholic hepatitis. N. Engl. J. Med. 2009, 360:2758-2769.
276. Adawi D., Kasravi F.B., Molin G., Jeppsson B. Effect of Lactobacillus supplementation with and without arginine on liver damage and bacterial translocation in an acute liver injury model in the rat. Hepatology 1997, 25:642-647.
277. Ewaschuk J., Endersby R., Thiel D., Diaz H., Backer J., Ma M., Churchill T., Madsen K. Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis. Hepatology 2007, 46:841-850.
278. Liu Q., Duan Z.P., Ha D.K., Bengmark S., Kurtovic J., Riordan S.M. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004, 39:1441-1449.
279. Rayes N., Hansen S., Seehofer D., Muller A.R., Serke S., Bengmark S., Neuhaus P. Early enteral supply of fiber and Lactobacilli versus conventional nutrition: a controlled trial in patients with major abdominal surgery. Nutrition 2002, 18:609-615.
280. Rayes N., Seehofer D., Hansen S., Boucsein K., Muller A.R., Serke S., Bengmark S., Neuhaus P. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 2002, 74:123-127.
281. Osman N., Adawi D., Ahrne S., Jeppsson B., Molin G. Endotoxin- and D-galactosamine-induced liver injury improved by the administration of Lactobacillus, Bifidobacterium and blueberry. Dig. Liver Dis. 2007, 39:849-856.
282. McClain C., Barve S., Joshi-Barve S., Song Z., Deaciuc I., Chen T., Hill D. Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease. Alcohol. Clin. Exp. Res. 2005, 29:180S-188S.
283. Tilg H., Jalan R., Kaser A., Davies N.A., Offner F.A., Hodges S.J., Ludwiczek O., Shawcross D., Zoller H., Alisa A., et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J. Hepatol. 2003, 38:419-425.
284. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., Siegel J.N., Braun M.M. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 2001, 345:1098-1104.
285. Yamada Y., Kirillova I., Peschon J.J., Fausto N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc. Natl. Acad. Sci. USA. 1997, 94:1441-1446.
286. Menon K.V., Stadheim L., Kamath P.S., Wiesner R.H., Gores G.J., Peine C.J., Shah V. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am. J. Gastroenterol. 2004, 99:255-260.
287. Boetticher N.C., Peine C.J., Kwo P., Abrams G.A., Patel T., Aqel B., Boardman L., Gores G.J., Harmsen W.S., McClain C.J., et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008, 135:1953-1960.
288. Osborn O., Brownell S.E., Sanchez-Alavez M., Salomon D., Gram H., Bartfai T. Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity. Cytokine 2008, 44:141-148.
289. Weisberg S.P., Hunter D., Huber R., Lemieux J., Slaymaker S., Vaddi K., Charo I., Leibel R.L., Ferrante A.W. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 2006, 116:115-124.
290. Barbuio R., Milanski M., Bertolo M.B., Saad M.J., Velloso L.A. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J. Endocrinol. 2007, 194:539-550.
291. Rachmilewitz D., Katakura K., Karmeli F., Hayashi T., Reinus C., Rudensky B., Akira S., Takeda K., Lee J., Takabayashi K., et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004, 126:520-528.
292. Pappo I., Bercovier H., Berry E., Gallilly R., Feigin E., Freund H.R. Antitumor necrosis factor antibodies reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat. JPEN J. Parenter. Enteral. Nutr. 1995, 19:80-82.
293. Bellentani S., Saccoccio G., Masutti F., Croce L.S., Brandi G., Sasso F., Cristanini G., Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 2000, 132:112-117.
294. Ruhl C.E., Everhart J.E. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin. Gastroenterol. Hepatol. 2005, 3:1260-1268.
295. Becker U., Gronbaek M., Johansen D., Sorensen T.I. Lower risk for alcohol-induced cirrhosis in wine drinkers. Hepatology 2002, 35:868-875.
296. Suzuki A., Angulo P., St Sauver J., Muto A., Okada T., Lindor K. Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia. Am. J. Gastroenterol. 2007, 102:1912-1919.
297. Dunn W., Xu R., Schwimmer J.B. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008, 47:1947-1954.
298. Wannamethee S.G., Camargo C.A., Manson J.E., Willett W.C., Rimm E.B. Alcohol drinking patterns and risk of type 2 diabetes mellitus among younger women. Arch. Intern. Med. 2003, 163:1329-1336.
299. Howard A.A., Arnsten J.H., Gourevitch M.N. Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann. Intern. Med. 2004, 140:211-219.
300. Zern T.L., Wood R.J., Greene C., West K.L., Liu Y., Aggarwal D., Shachter N.S., Fernandez M.L. Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J. Nutr. 2005, 135:1911-1917.
301. Castilla P., Echarri R., Davalos A., Cerrato F., Ortega H., Teruel J.L., Lucas M.F., Gomez-Coronado D., Ortuno J., Lasuncion M.A. Concentrated red grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects. Am. J. Clin. Nutr. 2006, 84:252-262.
302. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.